This phase 1 clinical trial will include patients with solid tumors in the breast, ovary, endometrium, skin, thyroid, lung, and prostate, and our findings suggest that GBM should be added to the list of cancers that could incorporate sortilin targeting as a therapeutic option. This evidence concerns the gene SORT1 and cancer.